Cutaneous T ‐cell lymphoma: 2017 update on diagnosis, risk‐stratification, and management
Abstract
Disease overviewCutaneous T‐cell lymphomas are a heterogenous group of T‐cell lymphoproliferative disorders involving the skin, the majority of which may be classified as Mycosis Fungoides (MF) or Sézary Syndrome (SS).
DiagnosisThe diagnosis of MF or SS requires the integration of clinical and histopathologic data.
Risk‐adapted therapyTNMB (tumor, node, metastasis, blood) staging remains the most important prognostic factor in MF/SS and forms the basis for a “risk‐adapted,” multi‐disciplinary approach to treatment. For patients with disease limited to the skin, expectant management or skin‐directed therapies is preferred, as both disease‐specific and overall survival for these patients is favorable. In contrast, patients with advanced‐stage disease with significant nodal, visceral or blood involvement are generally approached with biologic‐response modifiers or histone deacetylase inhibitors prior to escalating therapy to include systemic, single‐agent chemotherapy. In highly‐selected patients, allogeneic stem‐cell transplantation may be considered, as this may be curative in some patients.
Source: American Journal of Hematology - Category: Hematology Authors: Ryan A. Wilcox Tags: ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES Source Type: research
More News: Cancer & Oncology | Chemotherapy | Cutaneous T cell lymphoma | Hematology | Lymphoma | Mycosis Fungoides | Skin | Transplants